SAB Biotherapeutics, Inc. — fact timeline

SAB Biotherapeutics, Inc. entered into Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. valued at minimum aggregate spend following any FDA approval equal to $36 million (effective 2026-04-28).

“On April 28, 2026 (the “Effective Date”), SAB Biotherapeutics, Inc., a Delaware corporation (the “Company” or “SAB BIO”) entered into a Master Manufacturing Services Agreement (the “MSA”) with Emergent BioSolutions Canada Inc. (“Emergent”).”

SAB Biotherapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. valued at underwritten offering of common stock and pre-funded warrants (effective 2026-03-17).

“On March 17, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, UBS Securities LLC, Citigroup Capital Markets, Inc. and Barclays Capital Inc. (collectively, the “Representatives”) as the representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten offering (the “Offering”) of (i) 19,324,677 shares (the “Firm Shares”) of the Company’s common stock, $0.0001 par value per share (the “Common Stock”), at a price to the public of $3.85 per Firm Share, and (ii) pre-funded warrants to purchase up to 2,753,246 shares of Common Stock (the “Pre-Funded Warrants”), and such shares issuable upon the exercise of the Pre-Funded Warrants (the “Warrant Shares”), at a price to the public of $3.8499 per Pre-Funded Warrant, which represents the per share public offering price for the Firm Shares less the $0.0001 per share exercise price for each such Pre-Funded Warr”

SAB Biotherapeutics, Inc.: Filed Certificate of Designations creating Series B Convertible Preferred Stock (effective 2025-07-21).

“Pursuant to the terms of the Securities Purchase Agreement, on July 21, 2025, the Company filed the Certificate of Designations with the Delaware Secretary of State designating 2,811,429 shares of its authorized and unissued preferred stock as Series B Convertible Preferred Stock.”

Mark Conley changed role as Vice President of Finance at SAB Biotherapeutics, Inc..

“Mark Conley, who has been serving as Interim Chief Financial Officer since June 4, 2024, will reassume his prior position as the Company’s Vice President of Finance.”

Lucy To was appointed as Chief Financial Officer at SAB Biotherapeutics, Inc..

“On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.”

Mark Conley was appointed as Interim Chief Financial Officer at SAB Biotherapeutics, Inc..

“On May 30, 2024, Mark Conley, 62, was appointed Interim Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (the “Company”), effective June 4, 2024.”

Michael King, Jr. resigned as Chief Financial Officer at SAB Biotherapeutics, Inc..

“On May 26, 2024, Michael King, Jr., Chief Financial Officer of the Company, informed the Company that he will resign from his position with the Company, effective June 4, 2024, to pursue another opportunity.”

Dr. Jay S. Skyler was appointed as Class I director at SAB Biotherapeutics, Inc..

“On May 3, 2024, the Nominating and Corporate Governance Committee (the “ Committee ”) of the Board of Directors (the “ Board ”) of SAB Biotherapeutics, Inc., a Delaware corporation (the “ Company ”), recommended the appointment of, and the Board subsequently appointed, Dr. Jay S. Skyler to serve as a Class I director of the Company, effective as of May 3, 2024, and to serve until the Company’s 2025 annual meeting of stockholders or until Dr. Skyler’s successor is duly elected and qualified.”